Novartis to Partner with Banner Health on ApoE4 Prevention Trial Crenezumab Disappoints in Phase 2, Researchers Remain Hopeful Alzheimer’s Disease: In the Eye of the Patient? References and Thresholds—Amyloid Imaging Protocols Debated at AAIC Anti-Amyloid
Québec: Stem Cells in ALS Update Québec: Transporters, Antibodies Offer Potential ALS Therapies Québec: STOMPing on Inclusions May Reveal their True Identity Québec: Chromogranins Help SOD1 Do Its Dirty Work Researchers need to meet each year to advance t
Meet the New Progressive Tauopathy: CTE in Athletes, Soldiers Boxing: Study of Human Model for CTE Enters Second Round CTE: Trauma Triggers Tauopathy Progression Do Tau "Prions" Lead the Way From Concussions to Progression? CTE Needs Consensus o
Microglia Activation—Venusberg Meeting Questions M1, M2 Designations Inflammatory Crosstalk Between Periphery and Brain Blessing or Curse? Peripheral Cytokines in the Brain Glial Imaging—Amid Slow Progress, EU Project Takes Up Challenge Venusberg Meeting
Combination Drug Trials: Time to Open a New Front in AD? Combination Trials: FDA Puts Flesh on Bones of Draft Guidance Combination Trials: Companies Can Play Well in One Sandbox Building a Roadmap for Shared Combination Drug Trials ACT-AD FDA/AD Allies Me
Stockholm: Science Smorgasboard at Biannual Meeting Stockholm: New Strategies for Immunotherapy Stockholm: Therapeutics Roundup—Some New, Some Not So Much International Stockholm / Springfield Symposium on Advances in Alzheimer Therapy, 2012
Geneva: At Springfield Meeting, Soul-Searching About Dearth of Drugs Geneva: Biomarker News Morsels Amid Immunotherapy Review Geneva: The AstraZeneca Ligand—The Fairest of Them All? International Geneva/Springfield Symposium on Advances in Alzheimer Thera
Chicago—ALS Database Opens for Business Chicago—ALS Protein SOD1 Painted as Disease Template Chicago—ALS Clinical Trials: New Hope After Phase 3 Setbacks Chicago—Devilish Duo: Two Mutations Add Up to Familial ALS Chicago—Dynamic Repeats: C9ORF72 Expands a
Toronto: 6th Sense—GWAS Picks Up New AD Risk Variant Toronto: Mucke, Miller Share Prestigious Potamkin Prize Toronto: In Small Trial, IVIg Slows Brain Shrinkage American Academy of Neurology: 2010 Annual Meeting
Are TDP-43 Mice Living Up to Expectations? Arginine Methylation Distinguishes ALS-FUS From FTLD-FUS C9ORF72 Steals the Show at Frontotemporal Dementia Meeting TDP-43 Controls Blood Vessels in Fish, Is Phosphorylated in Worms Can Epigenetics Explain Variab
Taos: Biomarkers Keep Blooming, But Where’s the Fruit? Taos: Redox Redux—Putting the Oxidative Stress Theory to the Test Taos: Not the Usual Suspects: PARIS et al. Mark Progress in PD Keystone Symposium: Neurodegenerative Diseases: The Molecular and Cellu
Québec: Teasing Out the Function of TDP-43 Québec: Motor Neurons from Stem Cells—Really, Truly? Québec: In Zebrafish, Scientists See "ALS Matrix" Fondation André-Delambre, 2010 Symposium on Amyotrophic Lateral Sclerosis
World Alzheimer Conference 2000: De la Monte Receives Alzheimer Medal World Alzheimer Conference 2000: Symposium on ApoE World Alzheimer Conference 2000: Symposium on Therapeutic Approaches World Alzheimer Conference 2000: Drosophilae in the Emulsifier Wo
CNDR 2nd Annual Retreat: Welcome and Introduction CNDR 2nd Annual Retreat: Amyloid-binding Ligands as AD Therapies CNDR 2nd Annual Retreat: Gonadal Hormones Control β-Amyloid in Vivo CNDR 2nd Annual Retreat: Metal Complexing Agents as Therapies for AD CND